Pharma Mar (XMAD:PHM) Investments And Advances : €0.0 Mil (As of Mar. 2024)

View and export this data going back to 2000. Start your Free Trial

What is Pharma Mar Investments And Advances?

Pharma Mar's Investments And Advances for the quarter that ended in Mar. 2024 was €0.0 Mil.

Pharma Mar Investments And Advances Historical Data

The historical data trend for Pharma Mar's Investments And Advances can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Pharma Mar Investments And Advances Chart

Pharma Mar Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Investments And Advances

Get a 7-Day Free Trial

Pharma Mar Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Investments And Advances	Get a 7-Day Free Trial															-	-	-	-	-

Pharma Mar Investments And Advances Calculation

Investments And Advances includes all the non-current investments in affiliates, real estate, securities, etc.

Pharma Mar (XMAD:PHM) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Pharma Mar SA (XMAD:PHM) » Definitions » Investments And Advances

Comparable Companies

Traded in Other Exchanges

PHMMF:USA PHMe:UK 0RC6:UK

Address

Avenida de los Reyes, 1, Poligono Industrial La Mina-norte, Colmenar Viejo, Madrid, ESP, 28770

Website

http://www.pharmamar.com

Pharma Mar SA is engaged in the research, development, production, and commercialization of bio-active principles of marine origin for application in oncology. It also produces and market insecticides and air fresheners for household use, household products, wood treatment and decoration products, paints, and similar products. Its operating business segments are Oncology, Diagnostics, Consumer chemicals, and RNAi. The company obtains its revenues from two main areas: biopharmaceuticals and consumer chemicals, but the biopharmaceuticals is the main line of business.